Aripiprazole
Aripiprazole is one of 8,063 medications in the MedPlain dataset. Key details — Brand name: Aripiprazole; Generic name: ARIPIPRAZOLE; Drug class: Atypical Antipsychotic [EPC].
| Brand name | Aripiprazole |
|---|---|
| Generic name | ARIPIPRAZOLE |
| Drug class | Atypical Antipsychotic [EPC] |
| Manufacturer | VistaPharm, LLC |
| Used for | 1 INDICATIONS AND USAGE Aripiprazole Oral Solution is indicated for the treatment of: Schizophrenia [see CLINICAL STUDIES (14.1) ] Acute Treatment of Manic and Mixed Episodes associated with Bipolar I Disorder [see CLINICAL STUDIES (14.2) ] Adjunctive Treatment of Major Depressive Disorder [see CLINICAL STUDIES (14.3) ] Irritability Associated with Autistic Disorder [see CLINICAL STUDIES (14.4 ) ] Treatment of Tourette’s Disorder [see CLINICAL STUDIES (14.5) ] Aripiprazole is an atypical antipsychotic. The oral formulations are indicated for: Schizophrenia (14.1) Acute Treatment of Manic and Mixed Episodes associated with Bipolar I (14.2) Adjunctive Treatment of Major Depressive Disorder ( 1 |
| Dosage | 2 DOSAGE AND ADMINISTRATION Initial Dose Recommended Dose Maximum Dose Schizophrenia – adults (2.1) 10 to 15 mg/day 10 to 15 mg/day 30 mg/day Schizophrenia – adolescents (2.1) 2 mg/day 10 mg/day 30 mg/day Bipolar mania – adults: monotherapy (2.2) 15 mg/day 15 mg/day 30 mg/day Bipolar mania – adults: adjunct to lithium or valproate (2.2) 10 to 15 mg/day 15 mg/day 30 mg/day Bipolar mania – pediatric patients: monotherapy or as an adjunct to lithium or valproate (2.2) 2 mg/day 10 mg/day 30 mg/day M |
| Warnings | WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS; AND SUICIDAL THOUGHTS AND BEHAVIORS WITH ANTIDEPRESSANT DRUGS Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. Aripiprazole is not approved for the treatment of patients with dementia-related psychosis [see WARNINGS AND PRECAUTIONS (5.1) ] . Antidepressants increased the risk of suicidal thoughts and behavior in children, adolescents, and young adu |
| Active ingredient(s) | ARIPIPRAZOLE |
| Route | ORAL |
| Official label | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=06529caf-698f-41da-81ec-d0ba5ab200d7 |